Phospho-sulindac for Lung Cancer Treatment

磷酸舒林酸用于肺癌治疗

基本信息

批准号：
9333087
负责人：
Basil Rigas
金额：
$ 34.61万
依托单位：
STATE UNIVERSITY NEW YORK STONY BROOK
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-22 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9333087
关键词：
Address Adverse effects Animal Model Animals Anti-Inflammatory Agents Anti-inflammatory Antineoplastic Agents Antioxidants Apoptosis Biological Markers Butane Cancer Etiology Cell Cycle Progression Cell Line Cells Cessation of life Chemicals Clinical Cysteine Data Development Diagnosis Disease Dose Drug Combinations Early Diagnosis Early treatment Epidermal Growth Factor Receptor Equilibrium F2-Isoprostanes Free Radicals Genetic Glutathione Growth Human In Vitro Incidence Intravenous KRAS2 gene Lead Link Lung Neoplasms MAP Kinase Gene MAPK8 gene Malignant Neoplasms Malignant neoplasm of lung Maximum Tolerated Dose Mediating Modeling Molecular Target Mus Mutation NADPH Oxidase Neoplasm Metastasis Non-Small-Cell Lung Carcinoma Oxidation-Reduction Oxidative Stress Oxidative Stress Induction PIK3CG gene PTEN gene Patients Pharmaceutical Preparations Pre-Clinical Model Reactive Oxygen Species Safety Signal Pathway Signal Transduction Sulindac Superoxide Dismutase Superoxides Survival Rate System TXN gene Therapeutic Agents Therapeutic Effect Therapeutic Index Transgenic Model Work Xenograft procedure base cancer cell cancer therapy design dityrosine drug efficacy efficacy study in vivo lung cancer prevention lung small cell carcinoma member nanocarrier novel outcome forecast peroxiredoxin public health relevance response subcutaneous tumor tumor growth

Address Adverse effects Animal Model Animals Anti-Inflammatory Agents Anti-inflammatory Antineoplastic Agents Antioxidants Apoptosis Biological Markers Butane Cancer Etiology Cell Cycle Progression Cell Line Cells Cessation of life Chemicals Clinical Cysteine Data Development Diagnosis Disease Dose Drug Combinations Early Diagnosis Early treatment Epidermal Growth Factor Receptor Equilibrium F2-Isoprostanes Free Radicals Genetic Glutathione Growth Human In Vitro Incidence Intravenous KRAS2 gene Lead Link Lung Neoplasms MAP Kinase Gene MAPK8 gene Malignant Neoplasms Malignant neoplasm of lung Maximum Tolerated Dose Mediating Modeling Molecular Target Mus Mutation NADPH Oxidase Neoplasm Metastasis Non-Small-Cell Lung Carcinoma Oxidation-Reduction Oxidative Stress Oxidative Stress Induction PIK3CG gene PTEN gene Patients Pharmaceutical Preparations Pre-Clinical Model Reactive Oxygen Species Safety Signal Pathway Signal Transduction Sulindac Superoxide Dismutase Superoxides Survival Rate System TXN gene Therapeutic Agents Therapeutic Effect Therapeutic Index Transgenic Model Work Xenograft procedure base cancer cell cancer therapy design dityrosine drug efficacy efficacy study in vivo lung cancer prevention lung small cell carcinoma member nanocarrier novel outcome forecast peroxiredoxin public health relevance response subcutaneous tumor tumor growth

展开

项目摘要

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths, with a 5-year survival rate of <15%. This alarming prognosis makes clear the urgent need for new efficacious agents for its treatment. Phospho-sulindac (PS), a novel compound developed by us, inhibits the growth of lung cancer xenografts by 87-103%, eliminating, in one study, 3/7 lung cancer tumors. In addition to its remarkable efficacy, PS has an exceptional safety profile. Thus PS has a strong potential of becoming an efficacious agent for the treatment of lung cancer. Our preliminary data indicate that the mechanism of the anti-cancer effect of PS is, in its essence, the following: PS induces oxidative stress, which activates redox-sensitive signaling cascades, which in turn block cell cycle progression, inhibit proliferation and induce apoptosis; the end result is inhibition of tumor growth. The development of oxidative stress by PS is due to: a) activation of NADPH oxidase, which generates the free radical superoxide anion; and b) suppression of several members of the antioxidant system of the cell, both enzymatic (the thioredoxin system, peroxiredoxin, cytoglobin, superoxide dismutase) and chemical (glutathione).These effects increase rapidly the cellular levels of reactive oxygen species (ROS) shifting the redox balance towards oxidative stress. In vivo, co-administration of the antioxidant N-acetyl-cysteine and PS suppresses oxidative stress and eliminates the anticancer effect of PS on lung cancer xenografts. Our hypothesis is that PS is a highly effective and safe agent for the treatment of lung cancer acting predominantly by inducing oxidative stress. To evaluate this hypothesis, we propose the following specific aims: 1) Assess the efficacy of PS against lung cancer in animal tumor models: We will expand the efficacy studies to include xenografts of additional cell lines mirroring the genetic subtypes of lung cancer and a transgenic model of lung cancer. 2) Validate efficacy results in patient-derived lung cancer xenografts. They provide excellent prediction of drug efficacy in humans; we will study tumors with KRAS or EGFR mutations. And 3) Study in vitro and in vivo the molecular targets involved in the induction of oxidative stress by PS and the downstream signaling pathways that mediate its anticancer effect. We will evaluate the main contributors to oxidative stress and signaling pathways downstream of oxidative stress.

描述（由申请人提供）：肺癌是癌症死亡的主要原因，5年生存率<15％。这种令人震惊的预后清楚地表明，迫切需要对新的有效药物进行治疗。由美国开发的一种新型化合物磷酸硫酸（PS）抑制了87-103％的肺癌异种移植物的生长，在一项研究中消除了3/7肺癌肿瘤。除了其出色的功效外，PS还具有出色的安全性。因此，PS具有成为治疗肺癌的有效药物的强大潜力。我们的初步数据表明，PS的抗癌作用的机制在于本质，以下内容：PS诱导氧化应激，它激活了氧化还原敏感的信号级联反应，从而阻止细胞周期的进展，抑制增殖并诱导凋亡；最终结果是抑制肿瘤生长。 PS氧化应激的发展是由于：a）生成自由基超氧化阴离子的NADPH氧化酶的激活； b）抑制细胞抗氧化剂系统的几个成员，既酶促（硫氧还蛋白系统，过氧蛋白毒素，细胞糖蛋白，超氧化物歧化酶）和化学（谷胱甘肽）。这些作用迅速增加了反应性氧化物（ROS）转移氧化还原应力的反应性氧化物的细胞水平。在体内，抗氧化剂N-乙酰基半胱氨酸和PS的共同给药可抑制氧化应激，并消除PS对肺癌异种移植物的抗癌作用。我们的假设是，PS是一种高效且安全的药物，用于治疗肺癌主要通过诱导氧化应激而作用。为了评估这一假设，我们提出了以下特定目的：1）评估对肺癌模型中PS对肺癌的功效：我们将扩大疗效研究，包括反映肺癌遗传亚型和肺癌转基因模型的其他细胞系的异种移植。 2）验证疗效导致患者来源的肺癌异种移植物。他们提供了对人类药物疗效的极好预测。我们将研究具有KRAS或EGFR突变的肿瘤。 3）在体外和体内研究参与PS诱导氧化应激的分子靶标和介导其抗癌作用的下游信号传导途径。我们将评估氧化应激下游氧化应激和信号通路的主要因素。